Safety of Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation
Aim. To study the safety of non-vitamin K oral anticoagulants (NOAC) in patients with atrial fibrillation (AF) over 75 years old.Material and methods. The observation study included patients ≥75 years of age with confirmed AF, receiving dabigatran in a reduced dosage, apixaban or rivaroxaban in full...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2020-01-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/2071 |
| _version_ | 1797232135214465024 |
|---|---|
| author | M. A. Gabitova P. M. Krupenin A. A. Sokolova D. A. Napalkov V. V. Fomin |
| author_facet | M. A. Gabitova P. M. Krupenin A. A. Sokolova D. A. Napalkov V. V. Fomin |
| author_sort | M. A. Gabitova |
| collection | DOAJ |
| description | Aim. To study the safety of non-vitamin K oral anticoagulants (NOAC) in patients with atrial fibrillation (AF) over 75 years old.Material and methods. The observation study included patients ≥75 years of age with confirmed AF, receiving dabigatran in a reduced dosage, apixaban or rivaroxaban in full or reduced dosage. Previous experience of NOAC treatment from the very beginning of therapy, if a patient was ≥75 years old, or from the point a patient reached 75 years was considered; episodes of NOAK change, as well as hemorrhagic and ischemic events associated with taking an anticoagulant, were recorded. Patient groups were comparable in risk score by CHA2DS2-VASc and HAS-BLED scales.Results. Patients with AF (n=102; 39 men and 63 women; an average age 79.4Ѓ}4.1 years) were included: 32 patients were in dabigatran group, 34 patients – in apixaban group and 36 patients – in rivaroxaban group. 19 clinically significant bleedings were recorded, 10 occurred in patients taking dabigatran and 9 in those taking rivaroxaban. No hemorrhagic events in patients treated with apixaban were observed. Hematuria (31.6%), large subcutaneous hematomas (26.3%) and intensive nasal bleedings (26.3%) were the most frequent events. No ischemic cardioembolic stroke was recorded.Conclusions. In elderly patients, all NOAC (dabigatran, rivaroxaban and apixaban) demonstrated good safety profile without major bleeding within a 1.5-year follow-up period. |
| first_indexed | 2024-03-08T14:00:45Z |
| format | Article |
| id | doaj.art-136b6857804247dab034e22fedc14b85 |
| institution | Directory Open Access Journal |
| issn | 1819-6446 2225-3653 |
| language | English |
| last_indexed | 2024-04-24T15:55:27Z |
| publishDate | 2020-01-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj.art-136b6857804247dab034e22fedc14b852024-04-01T07:43:38ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532020-01-0115680280510.20996/1819-6446-2019-15-6-802-8051673Safety of Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial FibrillationM. A. Gabitova0P. M. Krupenin1A. A. Sokolova2D. A. Napalkov3V. V. Fomin4I.M. Sechenov First Moscow State Medical University (Sechenov University)I.M. Sechenov First Moscow State Medical University (Sechenov University)I.M. Sechenov First Moscow State Medical University (Sechenov University)I.M. Sechenov First Moscow State Medical University (Sechenov University)I.M. Sechenov First Moscow State Medical University (Sechenov University)Aim. To study the safety of non-vitamin K oral anticoagulants (NOAC) in patients with atrial fibrillation (AF) over 75 years old.Material and methods. The observation study included patients ≥75 years of age with confirmed AF, receiving dabigatran in a reduced dosage, apixaban or rivaroxaban in full or reduced dosage. Previous experience of NOAC treatment from the very beginning of therapy, if a patient was ≥75 years old, or from the point a patient reached 75 years was considered; episodes of NOAK change, as well as hemorrhagic and ischemic events associated with taking an anticoagulant, were recorded. Patient groups were comparable in risk score by CHA2DS2-VASc and HAS-BLED scales.Results. Patients with AF (n=102; 39 men and 63 women; an average age 79.4Ѓ}4.1 years) were included: 32 patients were in dabigatran group, 34 patients – in apixaban group and 36 patients – in rivaroxaban group. 19 clinically significant bleedings were recorded, 10 occurred in patients taking dabigatran and 9 in those taking rivaroxaban. No hemorrhagic events in patients treated with apixaban were observed. Hematuria (31.6%), large subcutaneous hematomas (26.3%) and intensive nasal bleedings (26.3%) were the most frequent events. No ischemic cardioembolic stroke was recorded.Conclusions. In elderly patients, all NOAC (dabigatran, rivaroxaban and apixaban) demonstrated good safety profile without major bleeding within a 1.5-year follow-up period.https://www.rpcardio.online/jour/article/view/2071atrial fibrillationnon-vitamin k oral anticoagulantselderlybleedingdabigatranrivaroxabanapixaban |
| spellingShingle | M. A. Gabitova P. M. Krupenin A. A. Sokolova D. A. Napalkov V. V. Fomin Safety of Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation Рациональная фармакотерапия в кардиологии atrial fibrillation non-vitamin k oral anticoagulants elderly bleeding dabigatran rivaroxaban apixaban |
| title | Safety of Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation |
| title_full | Safety of Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation |
| title_fullStr | Safety of Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation |
| title_full_unstemmed | Safety of Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation |
| title_short | Safety of Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation |
| title_sort | safety of non vitamin k oral anticoagulants in elderly patients with atrial fibrillation |
| topic | atrial fibrillation non-vitamin k oral anticoagulants elderly bleeding dabigatran rivaroxaban apixaban |
| url | https://www.rpcardio.online/jour/article/view/2071 |
| work_keys_str_mv | AT magabitova safetyofnonvitaminkoralanticoagulantsinelderlypatientswithatrialfibrillation AT pmkrupenin safetyofnonvitaminkoralanticoagulantsinelderlypatientswithatrialfibrillation AT aasokolova safetyofnonvitaminkoralanticoagulantsinelderlypatientswithatrialfibrillation AT danapalkov safetyofnonvitaminkoralanticoagulantsinelderlypatientswithatrialfibrillation AT vvfomin safetyofnonvitaminkoralanticoagulantsinelderlypatientswithatrialfibrillation |